

The board of directors of Swedish Orphan Biovitrum AB (publ) utilizes authorization to repurchase shares to secure the company's performance based, long-term share programs

The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) resolved on 27 April 2010 to issue not more than 1,552,949 series C shares to ensure that the company can fulfill its commitments under the performance based, long-term share programs 2008, 2009 and 2010 (the "Share Programs"). Furthermore, the Annual General Meeting resolved to authorize the board of directors to repurchase all issued series C shares for a price per share corresponding to the quota value of the company's share, i.e. in total approximately SEK 852,098. The series C shares will thereafter be converted to common shares in the number that is required to ensure delivery under the Share Programs.

The board of directors of the company has resolved to utilize the authorization for to repurchase all issued series C shares in accordance with the resolution by the Annual General Meeting on 27 April 2010.

The company currently holds 515,585 own series C shares.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical company with an international market presence. The company is focused on providing and developing specialist pharmaceuticals for rare disease patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipe-line. Our focus areas are: hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer and inherited metabolic disorders. Swedish Orphan Biovitrum had pro-forma revenues 2009e of about 2 BSEK and approximately 500 employees. The head office is located in Sweden and the share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information please visit www.sobi.com.

For more information please contact:

Erik Kinnman, Vice President Investor Relations

Phone: +46 73 422 15 40

E-mail: erik.kinnman@sobi.com

Swedish Orphan Biovitrum may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was provided for public release on December 23, 2010 at 12:00 p.m. (CET).